Global Immuno-Oncology Success
Newly-published case study shares successful approaches from an immuno-oncology study.
Newly-published case study shares successful approaches from an immuno-oncology study.
Phase III Trial for Melanoma Exceeds Enrollment Goals with Innovative Combination Therapy
In a newly-released case study, Medpace oncology experts review the challenges and solutions to this phase III registrational trial in patients with anti-PD-1 refractory melanoma using an intratumoral study drug in combination with I-O product ipilimumab.
Download the new case study to explore successful approaches from the recent immuno-oncology study:
Hematology & Oncology
An integrated Approach
With our proven full-service outsourcing model, Medpace delivers high-quality results. In the competitive field of hematology and oncology, we have earned a reputation for taking on some of the most complex and challenging cancer research studies.
- Global, in-house medical experts across a wide range of therapeutic areas, including hematology and oncology, and global regions, including Asia Pacific, Europe, and the US—demonstrated by 250+ hematology and oncology trials
- Comprehensive regulatory affairs and operational experts who work collaboratively with our medical team
- Expedited start-up and recruitment, including long-term site relationships and preferred CRO status with key Phase I hematology and oncology centers
- Integrated tumor imaging and central laboratory services, ensuring seamless logistics, review, and testing
